We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Faster, Simpler HIV Antibody Test

By HospiMedica staff writers
Posted on 07 Nov 2006
A new version of a rapid HIV-1 antibody test is simple to use and delivers results in less than three minutes.

The test, which detects HIV-1 antibodies in human serum or plasma, is based on a flow-through technology platform, and is comprised of a single-use test cartridge containing an immunoreactive test membrane. More...
A combination of synthetic peptides corresponding to conserved regions of HIV structural proteins coated onto a membrane matrix captures HIV-1 antibodies in serum or plasma when a drop of the specimen is applied.

The Reveal G3 antibody test, developed by MedMira (Halifax, Canada), is the third generation in the Reveal line of rapid HIV tests. The product's overall ease-of-use has been improved by the addition of MedMira's InstantGold Cap, which replaces the colorimetric detection agent used in the two previous versions of the test. The test package is now supplied in a box of 30, a new size format designed to maximize efficiency of all components. Reveal G3 has been cleared by the U.S. Food and Drug Administration (FDA).

"We are very pleased to receive approval on the third generation of Reveal, which brings to market key advancements that will drive further adoption of rapid HIV testing in point of care settings,” said Hermes Chan, president and CEO, MedMira. "HIV continues to be one of the greatest health challenges in the US [United States] and the healthcare system is taking steps to address the control and prevention of this epidemic.”

The recent U.S. Centers for Disease Control and Prevention (CDC, Atlanta GA) recommendations on routine HIV testing for everyone 13 to 64 years of age also included enhanced screening of pregnant women to decrease the rate of mother-to-child transmission. Key applications for MedMira's Reveal G3 test include labor and delivery, occupational exposures, and emergency departments.



Related Links:
MedMira

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Radiofrequency Generator
GX1
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.